Literature DB >> 10567693

X-ray diffraction study of feline leukemia virus fusion peptide and lipid polymorphism.

M J Darkes1, S M Davies, J P Bradshaw.   

Abstract

The structural effects of the fusion peptide of feline leukemia virus (FeLV) on the lipid polymorphism of N-methylated dioleoylphosphatidylethanolamine were studied using a temperature ramp with sequential X-ray diffraction. This peptide, the hydrophobic amino-terminus of p15E, has been proven to be fusogenic and to promote the formation of highly curved, intermediate structures on the lamellar liquid-crystal to inverse hexagonal phase transition pathway. The FeLV peptide produces marked effects on the thermotropic mesomorphic behaviour of MeDOPE, a phospholipid with an intermediate spontaneous radius of curvature. The peptide is shown to reduce the lamellar repeat distance of the membrane prior to the onset of an inverted cubic phase. This suggests that membrane thinning may play a role in peptide-induced membrane fusion and strengthens the link between the fusion pathway and inverted cubic phase formation. The results of this study are interpreted in relation to models of the membrane fusion mechanism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567693     DOI: 10.1016/s0014-5793(99)01454-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Fusion peptides promote formation of bilayer cubic phases in lipid dispersions. An x-ray diffraction study.

Authors:  Boris G Tenchov; Robert C MacDonald; Barry R Lentz
Journal:  Biophys J       Date:  2013-03-05       Impact factor: 4.033

2.  Neutron diffraction with an excess-water cell.

Authors:  Thad A Harroun; Kia Balai-Mood; Thomas Hauß; Toshiya Otomo; Jeremy P Bradshaw
Journal:  J Biol Phys       Date:  2005-05       Impact factor: 1.365

Review 3.  Common properties of fusion peptides from diverse systems.

Authors:  I Martin; J M Ruysschaert
Journal:  Biosci Rep       Date:  2000-12       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.